Priming Regimen For Patients With Refractory Or Relapsed Acute Myelogenous Leukemia (in Vivo And In Vitro)

Objective To explore priming regimen as an effective method of treatment in refractory or relapsed acute myeloid leukemia, and to analyse its mechanism by experimental data.Methods Twenty-seven cases of refractory or relapsed AML entered the study. We choice human monocytic leukemia cells SHI-1 by use of granulocyte colony-stimulating factor and homoharringtonine, cytarabine (Priming regimen) to observe differentiation and apoptosis in vitro.Results Among 27 cases of patients, 17 patients who received only one course of treatment achieved CR (61.9%). By two course of treatment six cases obtained CR (20.3%); four relapse cases had not achieved remssion. The growth and vitality SHI-1 cells were significantly inhibited; apoptosis detected by flow cytometry percentage was time and dose-dependent. The data showed that G1 and S phase cells were significantly reduced cell and blocked in G2 / M phase.Conclusion (1)Total efficiency of priming regimen for refractory or relapsed AML was 82.2%, and the hematological and non-hematological toxicity were low. (2) By priming regimen and low-dose HA regimen proliferation of the SHI-1 cells are inhibited and they induced cell differentiation and apoptosis, but the former was significant.